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Purpose: To screen the paired box gene 6 (PAX6) gene in irido-fundal coloboma.
Methods: The entire coding region of PAX6 including intron-exon boundaries was amplified from cases (n=30) and
controls (n=30). All sequences were analyzed against the ensemble sequence (ENSG00000007372) for PAX6.
Results:  DNA  sequence  analysis  of  patients  and  controls  revealed  a  total  of  three  nucleotide  changes  (g.
31815391Cytosine>Thymine;  Glycine72Glycine  and  g.31812215Thymine>Guanine)  of  which  one  was  neutral/
synonymous change and the remaining two were intronic changes. Of these 3 changes, 2 were novel and one was already
reported change. All these changes were non-pathogenic, according to in silico analysis.
Conclusions: In our study no pathogenic PAX6 mutation were identified. This suggests involvement of other coloboma
genes. This study expands the SNP spectrum of PAX6, only rare variations which are not causative have been found. Since
this is a pilot study in the north Indian population, results should be confirmed in different populations by similar studies.
Familial cases are required for determining the underlying genetic loci accounting for this clinical phenotype and may
lead to better understanding of disease pathogenesis.
Congenital malformations of the eyeball appear to occur
more frequently in certain countries like India and Sri Lanka,
accounting  for  approximately  25%  of  cases  of  visual
impairment  and  blindness  [1].  Ocular  coloboma  is  a
Figure 1. Fundus photograph in type I coloboma.
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congenital, common, and heterogeneous malformation which
includes a spectrum of anomalies ranging from iris coloboma
to clinical anophthalmos. Ocular coloboma, as an isolated
defect, is usually inherited as an autosomal dominant disorder,
although  autosomal  recessive  inheritance  also  occurs.
Coloboma is a hole in one of the structures of the eye, such as
the iris, retina, choroid, or optic disc. If coloboma is present
both in iris and retina it is known as irido-fundal coloboma.
According to coloboma location in the retina and whether it
involves the optic nerve or not, coloboma is classified into six
types by Gopal [2]: (I) this involves the optic nerve and is the
biggest type of coloboma (Figure 1). Vision is generally quite
poor in this type; (II) involves the optic nerve but it is smaller
than type I, so vision is poor but not as bad as in type I
coloboma; (III) this just misses the optic nerve (Figure 2) so
vision  can  be  quite  good.  However  if  associated  with
increased axial length and resulting high myopic refractive
error (spectacle number) the vision can be decreased; (IV) this
coloboma involves only the optic nerve but not much retina
that surrounds it. Vision can be good to average depending on
how much the optic nerve is distorted; (V) this coloboma is in
the periphery and does not involve the optic nerve as well as
the main area of the retina (Figure 3). As far as vision is
considered it is quite good in this type and any problem in
vision might not be noticed by the patient; (VI) these are
partially aborted attempts at forming coloboma. Vision is
unaffected in this type of coloboma.
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1414The estimated prevalence of coloboma is 1 in 10,000 in
the world population [3,4]. Coloboma associated with other
syndromes may cause up to 10% of the childhood blindness
[5]. The genetic basis of coloboma remains elusive. Recent
studies suggest that earlier developmental processes in eye are
controlled by a complex network of transcriptional factors,
cell cycle regulators and diffusible signaling molecules [6].
Paired box gene 6 (PAX6), a member of the paired box
family of transcription factors, has been identified as a key
regulator  of  eye  development  in  both  vertebrates  and
invertebrates [7-9]. During early mouse eye development,
expression of Pax6 has been shown in the presumptive lens
ectoderm, lens placode, lens vesicle and optic vesicle [10,
11]. At later stages, Pax6 is found in epithelia of conjunctiva,
cornea, lens, and ciliary body and in the neural retina [12,
13]. In humans, mutations in PAX6 have been demonstrated
in several patients with aniridia [14-17], a panocular disease
that is associated with iris hypoplasia, corneal opacification,
cataract, foveal dysplasia, and other diseases [18].
PAX6  is  located  on  chromosome  11p13  acts  as
transcriptional regulator of other genes that are associated
with coloboma. This gene contains 14 exons and encodes a
422-amino  acid  polypeptide  containing  two  DNA-binding
domains,  a  bipartite  paired  domain,  and  a  paired  type
homeodomain [19]. The paired domain, which is coded by
exons  5–7  of  PAX6,  has  two  subdomains:  the  relatively
conserved 74-amino acid NH2-terminal sub-domain and the
more divergent 54-amino acid COOH-terminal subdomain.
The latter sub-domain is a common place for mutations [19,
20]. Currently there are around 500 mutations that have been
reported (Human PAX6 Allelic Variant Database (HPAVD).
Most  PAX6  nonsense  mutations  lead  to  aniridia,  while
missense  mutations  are  related  to  foveal  hypoplasia,
congenital cataracts, or anterior segment anomalies [21,22].
Figure 2. Fundus photograph in type III coloboma.
In this preliminary pilot study we have screened PAX6
for mutations in irido-fundal coloboma patients (n=30) and
normal healthy controls (n=30).
METHODS
Patient selection and DNA isolation: The research followed
the tenets of the Declaration of Helsinki in the treatment of
the  subject  reported  herein.  The  study  was  approved  by
institutional review board (IRB # IRB00006862) of All India
Institute of Medical Sciences (AIIMS) and all participants
gave  their  written  informed  consent.  A  total  of  thirty
coloboma  patients  presented  at  the  Dr.  R.  P.  Centre  for
Ophthalmic  Sciences  (AIIMS,  New  Delhi,  India)  were
enrolled  in  this  study.  Clinical  evaluation  involved
fundoscopy (direct and indirect ophthalmoscopy), slitlamp-
biomicroscopy, and retinoscopy. Of these patients, 18 were
males and 12 were females. Mean age of presentation was
16.32 years. Diagnosis of coloboma involved the presence of
deficient of iris tissue and presence of coloboma in retina on
clinical examination. All cases were sporadic without any
family history. All cases secondary to causes like trauma etc.
were excluded from the study.
After informed consent, detailed personal, medical, and
occupational history was collected and a family tree up to
three  generations  was  drawn.  Thirty  ethnically  matched
normal individuals without any ocular disorder were enrolled
as controls. Health information was obtained from controls
through the questionnaire; all underwent ophthalmological
examination and a blood sample (5 ml) was collected in EDTA
(EDTA)  vacutainers  (Greiner  Bio-One,  GmbH,
Frickenhausen, Germany) from patients and controls for DNA
extraction. DNA was extracted from whole blood samples of
all patients and controls using the phenol-chloroform method.
Figure 3. Fundus photograph in type V coloboma.
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1415Polymerase chain reaction (PCR) and DNA Sequencing: All
coding regions of PAX6 including exon-intron junctions were
amplified using a set of eight oligonucleotide primers (Table
1).  These  primers  were  designed  using  NCBI  PRIMER3
program.
TABLE 1. PRIMERS USED FOR PAX6 AMPLIFICATION.
Sample
number Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′)
Product size
(bp)
Annealing
temp (°C)
1 GGAGTTCAGGCCTACCTGATGCAG GAGAAGAGCCAAGCAAACGCCCTC 313 55
2 CGCCGAGGTTGGCACAGGTT AGCATGGGCTGGGGAGAGCA 710 55
3 CGTTTTGATGCATCTTCAGGCAGTG GGGCATTCCTCTCTGTTCCCCCA 703 62
4 TGGTGAAGGACCCCCTCCGC ACACACACGCACCCACCAGC 647 61
5 ACCAGGCCCCTTTTGGAGGCT TGGCATTCAGTGACCTTTCTGTGGC 554 62
6 GGAGTGGGGAGGTGGGAACCA AGGCCCTGAGCCACTCCTCAC 837 60
7 AGCTGTGGCCAGTGGAAGGAC TGGGCCCCCTACTGAGCTTCG 636 62
8 TCCTTTGGATTGGGGTGGGGG CGTGGCAAAGCTTGTTGATCATGG 713 62
TABLE 2. CLINICAL MANIFESTATIONS OF CASES WITH IRIDO-FUNDAL COLOBOMA.
Patient
ID
Age
(years) Sex Iridofundla coloboma type
Axial length
(RE;LE)
Visual acuity
(RE;LE) Treatment
IFC1 15 M B/L Type II IFC 21.62;21.59 3/60; 3/60 B/L laser
IFC2 7 F B/LType I IFC + microophthalmia
+microcornea + nystagamus
24.26;25.50 2/60; 1/60 Laser not possible due to
extreme microcornea
IFC3 17 F LE Inferonasal + IFC type III 20.64;20.33 6/6; PL +ve LE laser
IFC4 7 M B/L IFC type I 19.25;22.20 PL+; PL +ve No laser done
IFC5 10 F B/L microophthalmia
+microcornea + nystagamus +
type II IFC
20.21;20.85 1/60;1/60 No laser done due to extreme
microcornea
IFC6 27 M B/L Nystagymus + type II IFC 26.22; 22.71 FCCF;FCCF B/L laser
IFC7 13 F RE IFC type II + amblyopia 24.81;22.69 FCCF;6/12 RE laser
IFC8 28 M LE type III IFC 22.84;21.77 6/6; 6/60 L/E laser
IFC9 26 M RE IFC type III 26.11;22.60 6/24; 6/6 RE laser
IFC10 16 F B/L IFC type I 24.50;24.60 1/60;2/60 B/L laser
IFC11 10 F RE IFC type III 21.54;20.70 Patient non-
cooperative
RE laser
IFC12 7 M RE IFC; L Iris coloboma; B/L
microcornea
20.01; 20.39 FCCF;6/60 B/L laser
IFC13 3 M B/L (microophthalmia
+microcornea + distichiasis + IFC
type I
20.08;22.00 FCCF;1/60 B/L laser
IFC14 20 M RE IFC type II coloboma 25.25;23.50 HMCF/6/24 R/L laser
IFC15 5 M B/L type II IFC 21.91/21.02 6/60; 6/36 B/L laser
IFC16 11 M B/L microophthalmia + type II
IFC
22.65;21.80 3/60;6/60 B/L laser
IFC17 11 M B/L type I IFC with squint 18.25; 22.45 1/60; 2/60 B/L laser
IFC18 9 M B/L microophthalmia + IFC type I 22.45; 23.10 PL+; 1/60 B/L laser
IFC19 19 F B/L microcornea + type II IFC 22.12; 22.70 1/60; 3/60 B/L laser
IFC20 28 F B/L IFC type III + nystagamus 26.18; 27.66 HMCF/6/60 B/L laser
IFC21 15 M LE IFC type II 22.73; 26.73 6/6; HMCF L laser
IFC22 33 M B/L IFC type III 21.35; 21.50 6/36; 6/36 B/L laser
IFC23 33 M B/L IFC type IV 24.09; 24.24 6/60; 1/60 B/L laser
IFC24 30 M B/L IFC type IV + microcornea +
nystagymous
29.55; 24.99 HMCF; FC2M B/L laser
IFC25 25 M RE type I IFC; LE type V IFC 26.81; 23.71 HMCF/6/6 B/L laser
IFC26 17 M B/L type III IFC 24.35; 24.50 6/18, 6/18 B/L laser
IFC27 14 M B/L IFC Type I 26.25; 25.90 1/60; 2/60 B/L laser
IFC28 15 M LE type III IFC + Microcornea 22.50; 22.24 6/6;6/60 LE laser
IFC29 6 F RE IFC type III; LE type II IFC 24.45; 25.50 6/60; 2/60 B/L laser
IFC30 12 M B/L type V IFC 23.50;22.80 6/9; 6/12 B/L laser
        Key: IFC represents Iridofundal coloboma; LE represents Left eye; RE represents Right eye; FCCF represents Finger counting
        close to face; HMCF represents Hand motion close to face; PL represents Perception of light.
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1416Each  reaction  was  performed  in  a  25  µl  mixture
containing 0.2 µM each primer, 0.5 U Taq DNA polymerase,
2.5 µl of 10× PCR buffer (Biogene, New Delhi, India) with
2.5 mM MgCl2, and approximately 100 ng genomic DNA.
PCR was performed in thermal cycler (My Cycler; BioRad,
Gurgaon, India) under the conditions shown in Table 1.
All PCR products were analyzed on 1.8% agarose gel
stained with ethidium-bromide (EtBr; 10 mg/ml). Agarose
gels  were  analyzed  using  the  Gel  Documentation  System
(Applied  Biosystems,  Carlsbad,  CA).  Amplified  PCR
products  were  purified  using  gel/PCR  DNA  fragments
extraction kit (Catalog number DF100; Geneaid Biotech Ltd.,
Sijhih City, Taiwan). Purified PCR products were outsourced
for sequencing at Molecular Cloning Laboratories (MCLAB,
South San Francisco, CA).
DNA sequences were compared with the human PAX6
reference sequence.
Insilico analysis for predicting pathogenicity of mutations:
An  improved  splice  site  predictor  tool  [23]  was  used  for
predicting  the  effect  of  an  intronic  nucleotide  change  on
splicing of PAX6 mRNA.
RESULTS
DNA sequence analysis of patients and controls revealed a
total of three nucleotide changes. Of which one was neutral/
synonymous and novel change. The remaining two changes
were intronic, one of which was novel. Details of these cases
are tabulated (Table 2).
g.31815391Cytosine>Thymine:  A  novel  single
nucleotide  change  from  cytosine  (C)  to  thymine  (T)  at
genomic position g. 31815391 (Figure 4) was present in one
case but absent in controls. The alteration is located in intron
9 (IVS9+40). This change was registered at GenBank with
accession number HQ397715.
g.31823250 Thymine>Guanine: In this mutation a single
nucleotide T was replaced by guanine (G) at genomic position
g.31823250; cDNA position c.216; codon 72 resulted in a
codon  change  GGT>GGG  which  predicts  a  synonymous
change p.Gly72Gly (p.G72G; Figure 5). This change was
present as heterozygous change in 29 cases and 20 controls;
and as a homozygous change in one case. This change was
novel  and  registered  at  GenBank  with  accession  number
HQ397714.
g.31812215Thymine>Guanine:  A  single  nucleotide
change from T to G at genomic position g.31812215 (Figure
6) was present in six cases and one control. The alteration is
located in intron 12 (IVS13–42).
Improved splice site prediction for both intronic changes
showed that the location of these changes is not present at a
splice site and may not create splicing error in the PAX6
protein.
DISCUSSION
The genetic basis of coloboma remains elusive. Recent studies
suggest  that  earlier  developmental  process  in  the  eye  are
controlled by a complex network of transcriptional factors,
cell cycle regulators, and diffusible signaling molecules [6].
Mutations in these genes may lead to ocular coloboma. It has
been proposed that PAX6 acts as a transcriptional regulator
of many other genes involved in ocular development. PAX6
mutations have been identified in sporadic aniridia cases from
different populations [17] as well as in familial aniridia cases
[14-16]. In this study we have screened PAX6 in irido-fundal
coloboma patients and controls and we observed 3 changes (2
intronic  changes  and  one  synonymous/neutral  change).
Figure  4.  DNA  sequence  of  PAX6  equivalent  to  g.31815399  to
31815385. A: The reference sequence derived from the control is
shown. B: The sequence derived from patient shows a heterozygous
C>T mutation at g.31815391.
Figure 5. DNA sequence of PAX6 equivalent to codon 71–75. A: The
reference sequence derived from the control shows the heterozygous
c.216T>G change which predicts a codon change from GGT>GGG
and p.G72G mutation. B: The sequence derived from another patient
shows a homozygous p.G72G mutation.
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1417However, no pathogenic PAX6 mutation was identified in our
patients.
Mutations in PAX2 were identified in individuals with
ocular coloboma in renal coloboma syndrome [24]. PAX2 is
a member of a multi-gene family containing a paired box
domain that was identical in Drosophila and subsequently in
vertebrates [25]. PAX2 expression is critical for development
of urogenital tract, central nervous system (CNS), inner ear,
and optic nerve. Further studies suggest that PAX2 mutations
are not common in patients with isolated ocular coloboma and
associated anomalies [26].
The absence of PAX6 mutations in our study population
suggests the involvement of other coloboma genes showed by
Zhang et al. [27]. This study expands the SNP spectrum of
PAX6, only rare variations which are not causative have been
found. Since this is a pilot study in the north Indian population,
our results should be confirmed in different populations by
similar studies. However, the absence of PAX6 mutations in
selected  population  do  not  rule  out  the  possibility  of
involvement of this gene in coloboma. Friling et al. [28] have
shown the deletion of the whole gene (11p) in a patient with
uveal colobomata. So there is still a possibility for PAX6 to be
involved in coloboma cases which can be detected by CGH
array. As the frequency of the congenital blindness is more in
Asian countries [18], where a majority of the population has
vitamin A deficiency which is required for normal expression
of several genes involved in ocular morphogenesis. Vitamin
A is critical during eye development and optic fissure fails to
close in vitamin A deficient embryos [29]. It has been reported
that Pitx2 expression is downregulated in vitamin A deficient
embryos and this gene is required for optic fissure closure.
Epidemiological evidences has shown the teratogenic effect
Figure  6.  DNA  sequence  of  PAX6  equivalent  to  g.31812220  to
31812209. A: The reference sequence derived from the control is
shown. B: The sequence derived from patient shows a homozygous
g.31812215T>G mutation.
of vitamin A deficiency during pregnancy. Thus screening of
the  candidate  gene  is  required  in  large  number  of  cases.
Familial  cases  are  required  for  determination  of  the
underlying genetic loci accounting for this clinical phenotype
which  may  lead  to  better  understanding  of  disease
pathogenesis in near future.
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